Product Overview

AOP Orphan's focus is on rare and special diseases. The portfolio comprises products in the following therapeutic areas: HematoOncology, Cardiology & Pulmonology, Neurology and Metabolic Disorders and Intensive Care. AOP Orphan’s strategic goal is to constantly deliver new treatment options with respect to rare and special diseases. 

Neurology & Metabolic Disorders

Adasuve®

is indicated for the rapid control of mild-to-moderate agitation (increased, unproductive physical activity coupled with internal tension) in adult patients with schizophrenia or biopolar disorder. 

Drug Facts
Active Ingredient
Loxapine
Neurology & Metabolic Disorders

Adepend® Dependex®

Adepend is used as part of a comprehensive treatment programme against alcoholism to reduce the risk of relapse, as support treatment in abstinence and to reduce the craving for alcohol.

Drug Facts
Active Ingredient
Naltrexone
HematoOncology

Anagrelide AOP

Anagrelide AOP is indicated in Essential Thrombocythemia for the reduction of elevated platelet counts and associated clinical symptoms in at high risk patients

Drug Facts
Active Ingredient
Anagrelide
HematoOncology

BESREMi®

BESREMi® is indicated as monotherapy in adults for the treatment of Polycythaemia Vera without symptomatic splenomegaly.

Drug Facts
Active Ingredient
Ropeginterferon alfa-2b
Intensive Care

Empressin®

Empressin® is used for the treatment of catecholamine refractory hypotension following septic shock in patients older than 18 years. A catecholamine refractory hypotension is present if the mean arterial blood pressur cannot be stabilized to 65 – 75 mmHg despite adequate volume substitution and application of catecholamines.

Drug Facts
Active Ingredient
Agripressin
Neurology & Metabolic Disorders

Ocaliva®

Ocaliva® is indicated for the treatment of primary biliary cholangitis (also known to as primary biliary cirrhosis) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.

Drug Facts
Active Ingredient
Obeticholic acid
Intensive Care

Rapibloc ®

Landiolol hydrochloride is indicated for supraventricular tachycardia and for rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short acting agent is desirable. Landiolol hydrochloride is also indicated for non-compensatory sinus tachycardia where, in the physician’s judgment the rapid heart rate requires specific intervention. Landiolol is not intended for use in chronic settings.

Drug Facts
Active Ingredient
Landiolol
Neurology & Metabolic Disorders

Tetmodis®

Tetmodis® is used as symptomatic therapy in the treatment of hyperkinetic motor disorders in Huntington’s disease.

Drug Facts
Active Ingredient
Tetrabenazine
Neurology & Metabolic Disorders

Wakix®

Wakix® is indicated in adults for the treatment of narcolepsy with or without cataplexy.

Drug Facts
Active Ingredient
Pitolisant